In:
International Journal of Cancer, Wiley, Vol. 46, No. 4 ( 1990-10-15), p. 727-732
Abstract:
Two sublines were derived from the colon adenocarcinoma line LoVo, the first one was sensitive (LoVo/H) and the second one was made resistant to doxorubicin (LoVo/Dx). When tested for susceptibility to lysis by different types of immune effectors, LoVo/Dx appeared more sensitive than LoVo/H to the killing of CD3 + CDS + CD16 − , CD3 − CD16 + ‐enriched lymphokine activated killers (LAK) or activated macrophages. In order to check whether this effect was due to different expression of glycoprotein PI70 between the two LoVo sublines (30% vs. 90% of positive cells), a pharmacological and genetic modulation of PI70 was carried out in LoVo cells. Treatment of LoVo/Dx with the calcium channel blocker verpamil (VRP), strongly impaired PI70 function as evaluated by reduced Dx resistance, without affecting the lysability of LoVo/Dx cells by LAKs. Moreover, the significant inhibition of PI70 expression resulting from the treatment of LoVo/Dx with mdr l antisense olideoxynucleotide also failed to change the high lysability of LoVo/Dx by LAKs. These results, therefore, indicate that molecules other than PI70 are involved in the increased lysis of LoVo/Dx subline by immune effectors and that downregulation of the PI70 expression or function will not reduce the potential effectiveness of cancer chemo‐immunotherapy.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
DOI:
10.1002/ijc.2910460429
Language:
English
Publisher:
Wiley
Publication Date:
1990
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8
Permalink